Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Radnet ( (RDNT) ) just unveiled an announcement.
On March 2, 2026, RadNet announced it had acquired Paris-based radiology AI specialist Gleamer SAS for up to €230 million in an all-cash deal, including a €15 million milestone payment. Gleamer, which serves more than 700 customer contracts in 44 countries with FDA-cleared and CE-marked AI solutions, will be integrated into RadNet’s DeepHealth digital health division.
The combination of Gleamer’s cloud-first, multimodality portfolio and DeepHealth’s existing clinical AI suites makes DeepHealth the largest provider of radiology clinical AI solutions worldwide. RadNet expects the integration and deployment of Gleamer’s technology across its network, particularly in high-volume X-ray workflows, to boost productivity, enhance automated exam prioritization and draft reporting, and deliver operational and cost efficiencies by the third quarter of 2026.
Gleamer’s rapid ARR growth and broad product portfolio, together with DeepHealth’s global footprint, are set to create a comprehensive AI platform spanning MR, CT, X-ray, mammography and ultrasound. The move strengthens RadNet’s competitive positioning in AI-enabled imaging at a time of rising imaging volumes and radiologist shortages, with implications for improved access, standardized interpretation and patient outcomes across multiple major disease areas.
The most recent analyst rating on (RDNT) stock is a Hold with a $76.00 price target. To see the full list of analyst forecasts on Radnet stock, see the RDNT Stock Forecast page.
Spark’s Take on RDNT Stock
According to Spark, TipRanks’ AI Analyst, RDNT is a Neutral.
The score is held back primarily by weaker profitability/leverage in financials and bearish technical trends (below key moving averages with weak momentum). These are partially offset by a strong earnings call featuring record results and raised guidance, while valuation is constrained by a sharply negative P/E and no dividend support.
To see Spark’s full report on RDNT stock, click here.
More about Radnet
RadNet, Inc. is a leading U.S. provider of freestanding, fixed-site outpatient diagnostic imaging services, operating a large network of centers across states including California, New York and Texas. Through its DeepHealth subsidiary, the company also offers radiology information technology, teleradiology and AI-powered health informatics solutions to imaging providers worldwide.
DeepHealth focuses on AI-driven operational efficiency and improved clinical outcomes in breast, chest, neuro, prostate and thyroid care, anchored by its cloud-first DeepHealth OS platform. Thousands of imaging centers and radiology departments globally use its tools to support earlier, more reliable and efficient disease detection, including in large-scale cancer screening programs.
Average Trading Volume: 833,664
Technical Sentiment Signal: Buy
Current Market Cap: $5.4B
Find detailed analytics on RDNT stock on TipRanks’ Stock Analysis page.